<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 07 May 2021 11:32:10 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>刚刚！百济神州PARP抑制剂「帕米帕利」获批上市</title><link>https://mp.weixin.qq.com/s/cCgLYxrkArOIcXGHWHKv6g</link><description></description><content:encoded><![CDATA[刚刚！百济神州PARP抑制剂「帕米帕利」获批上市]]></content:encoded><pubDate>Fri, 07 May 2021 11:07:07 +0800</pubDate></item><item><title>百济神州第一季度业绩，替雷利珠单抗3.17亿元</title><link>https://mp.weixin.qq.com/s/VK4lUK8Hkvipr_FYF05FEA</link><description></description><content:encoded><![CDATA[百济神州第一季度业绩，替雷利珠单抗3.17亿元]]></content:encoded><pubDate>Fri, 07 May 2021 11:07:07 +0800</pubDate></item><item><title>13家跨国药企一季度业绩汇总</title><link>https://mp.weixin.qq.com/s/90aYuT60c1GdKV7QayY7mg</link><description></description><content:encoded><![CDATA[13家跨国药企一季度业绩汇总]]></content:encoded><pubDate>Thu, 06 May 2021 18:07:38 +0800</pubDate></item><item><title>PD-1+HER2+化疗组合疗法获FDA批准，一线治疗胃癌</title><link>https://mp.weixin.qq.com/s/XhwYc-HMmzgnXJu56WKEjw</link><description></description><content:encoded><![CDATA[PD-1+HER2+化疗组合疗法获FDA批准，一线治疗胃癌]]></content:encoded><pubDate>Thu, 06 May 2021 18:07:38 +0800</pubDate></item><item><title>罗氏「艾美赛珠单抗」新适应症即将获批</title><link>https://mp.weixin.qq.com/s/URcgtAsi2OFGEkdvLL89Qg</link><description></description><content:encoded><![CDATA[罗氏「艾美赛珠单抗」新适应症即将获批]]></content:encoded><pubDate>Thu, 06 May 2021 18:07:38 +0800</pubDate></item><item><title>医药魔方前沿趋势研究主题分享会 | 苏州站</title><link>https://mp.weixin.qq.com/s/adL-319WJG7uVxN1xi4ZXg</link><description></description><content:encoded><![CDATA[医药魔方前沿趋势研究主题分享会 | 苏州站]]></content:encoded><pubDate>Thu, 06 May 2021 18:07:38 +0800</pubDate></item><item><title>注射剂一致性评价排行榜（附已过评清单）</title><link>https://mp.weixin.qq.com/s/j06CRB1ij0R1smPnPX-Edg</link><description></description><content:encoded><![CDATA[注射剂一致性评价排行榜（附已过评清单）]]></content:encoded><pubDate>Wed, 05 May 2021 10:08:09 +0800</pubDate></item><item><title>医药魔方前沿趋势研究主题分享会 | 苏州站</title><link>https://mp.weixin.qq.com/s/dOQpXNfwsdlXujsGAHnSAw</link><description></description><content:encoded><![CDATA[医药魔方前沿趋势研究主题分享会 | 苏州站]]></content:encoded><pubDate>Wed, 05 May 2021 10:08:09 +0800</pubDate></item><item><title>20年来重大进展！「达格列净」获FDA批准治疗慢性肾病</title><link>https://mp.weixin.qq.com/s/w2pI8MaH5pC07yIjBZ9_Tw</link><description></description><content:encoded><![CDATA[20年来重大进展！「达格列净」获FDA批准治疗慢性肾病]]></content:encoded><pubDate>Sat, 01 May 2021 08:57:40 +0800</pubDate></item><item><title>2021年4月 | FDA批准的新药</title><link>https://mp.weixin.qq.com/s/26IbnSeixDzqJ_YwkSKJuw</link><description></description><content:encoded><![CDATA[2021年4月 | FDA批准的新药]]></content:encoded><pubDate>Sat, 01 May 2021 08:57:40 +0800</pubDate></item><item><title>医药魔方前沿趋势研究主题分享会 | 苏州站</title><link>https://mp.weixin.qq.com/s/vZncn90UimGgdXuh8ByloA</link><description></description><content:encoded><![CDATA[医药魔方前沿趋势研究主题分享会 | 苏州站]]></content:encoded><pubDate>Sat, 01 May 2021 08:57:40 +0800</pubDate></item><item><title>百济神州PARP抑制剂「帕米帕利」即将获批上市</title><link>https://mp.weixin.qq.com/s/531lQ0NcuIiw2Xav-6pUWw</link><description></description><content:encoded><![CDATA[百济神州PARP抑制剂「帕米帕利」即将获批上市]]></content:encoded><pubDate>Fri, 30 Apr 2021 18:04:40 +0800</pubDate></item><item><title>靶向泛FGFR：信达生物 vs 联拓生物</title><link>https://mp.weixin.qq.com/s/g4vyd1sNfx2GjkDbCwYWfg</link><description></description><content:encoded><![CDATA[靶向泛FGFR：信达生物 vs 联拓生物]]></content:encoded><pubDate>Fri, 30 Apr 2021 18:04:40 +0800</pubDate></item><item><title>首个NMOSD治疗药物即将在华获批上市</title><link>https://mp.weixin.qq.com/s/eYgrciHIJ-Ma55t7QIPDSw</link><description></description><content:encoded><![CDATA[首个NMOSD治疗药物即将在华获批上市]]></content:encoded><pubDate>Fri, 30 Apr 2021 18:04:40 +0800</pubDate></item><item><title>医药魔方前沿趋势研究主题分享会 | 苏州站</title><link>https://mp.weixin.qq.com/s/-Rx7V3KGSZwuzTrOWn2v0Q</link><description></description><content:encoded><![CDATA[医药魔方前沿趋势研究主题分享会 | 苏州站]]></content:encoded><pubDate>Fri, 30 Apr 2021 18:04:40 +0800</pubDate></item><item><title>改良新药「布地奈德缓释胶囊」获FDA优先审评，治疗IgA肾病！中国已纳入突破性疗法</title><link>https://mp.weixin.qq.com/s/h3-eMjzCPK8MbTZvJYkKeg</link><description></description><content:encoded><![CDATA[改良新药「布地奈德缓释胶囊」获FDA优先审评，治疗IgA肾病！中国已纳入突破性疗法]]></content:encoded><pubDate>Thu, 29 Apr 2021 16:53:29 +0800</pubDate></item><item><title>20年来首个全新机制抗流感新药！罗氏「玛巴洛沙韦片」在华获批上市</title><link>https://mp.weixin.qq.com/s/a58JjTlbEYpk-N2WaHKk-Q</link><description></description><content:encoded><![CDATA[20年来首个全新机制抗流感新药！罗氏「玛巴洛沙韦片」在华获批上市]]></content:encoded><pubDate>Thu, 29 Apr 2021 16:53:29 +0800</pubDate></item><item><title>全球首个CD38单抗新适应症在华获批，2020年销售额41.9亿美元</title><link>https://mp.weixin.qq.com/s/qwuDXmt-lF45-_u0-KFChA</link><description></description><content:encoded><![CDATA[全球首个CD38单抗新适应症在华获批，2020年销售额41.9亿美元]]></content:encoded><pubDate>Thu, 29 Apr 2021 16:53:29 +0800</pubDate></item><item><title>医药魔方前沿趋势研究主题分享会 | 苏州站</title><link>https://mp.weixin.qq.com/s/Z3ibAQJ8Zv0C5VSCSSWs-Q</link><description></description><content:encoded><![CDATA[医药魔方前沿趋势研究主题分享会 | 苏州站]]></content:encoded><pubDate>Thu, 29 Apr 2021 16:53:29 +0800</pubDate></item><item><title>恒瑞PD-1鼻咽癌适应症获批</title><link>https://mp.weixin.qq.com/s/ZHQFTKQEp8XU6hiPJnKlQA</link><description></description><content:encoded><![CDATA[恒瑞PD-1鼻咽癌适应症获批]]></content:encoded><pubDate>Thu, 29 Apr 2021 16:53:29 +0800</pubDate></item></channel></rss>